Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Burkitt Lymphoma 1

Interventions

Cisplatin 18 Magnetic Resonance Spectroscopy 14 Specimen Handling 12 Gemcitabine 12 Carboplatin 12 pembrolizumab 11 Paclitaxel 9 Platinum 7 Pemetrexed 7 1,2-diaminocyclohexaneplatinum II citrate 7 atezolizumab 6 Radiotherapy, Intensity-Modulated 6 Radiotherapy 6 Radiation 6 Nivolumab 6 Doxorubicin 6 Surgical Procedures, Operative 5 Rituximab 5 Immunoglobulin G 5 Docetaxel 5 Disulfides 5 Biopsy 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 Temozolomide 4 Drug Therapy 4 Dexamethasone 4 Cyclophosphamide 4 Cetuximab 4 venetoclax 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Diphenhydramine × 30 days × Clear all

NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡